CT
Cellula Therapeutics at BIO-Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
Cellula Therapeutics takes part in 2 sessions at BIO-Europe 2026 in Cologne. Its sessions centre on clinical strategy, covering how to plan the development of first-in-class therapeutics and how mission-driven investment balances capital with clinical impact. The first-in-class session is shared with NMD Pharma.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
CT Cellula Therapeutics Epalinges, Switzerland | |
Swiss cell therapy biotech spun out of the University of Geneva. | Panel Wed Nov 11 10:30–10:55 Building a Clinical Strategy for First-in-Class Therapeutics How bold phase 3 trial designs, such as adaptive trials that change as data arrive, can help a first-of-its-kind rare disease drug succeed. Panel Wed Nov 11 11:00–11:45 Mission-Driven Investments: Balancing Capital and Clinical Impact Funding barriers that hold back clinical trials, ways to cut their costs, and investments that weigh patient benefit alongside financial return. |
Instantly find 20 buyers from Cellula Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction